Bullish pennant formed just prior to FDA putting a partial hold on Inovio's Covid-19 vaccine P2/P3 trials. Inovio is expected to resolve the FDA's questions within the next 30 days and begin trials with "EXTENSIVE external funding" according to CEO - Dr. Joseph Kim
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.